These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 24578251)

  • 21. Exploring Uncertainty in Economic Evaluations of Drugs and Medical Devices: Lessons from the First Review of Manufacturers' Submissions to the French National Authority for Health.
    Ghabri S; Hamers FF; Josselin JM
    Pharmacoeconomics; 2016 Jun; 34(6):617-24. PubMed ID: 26829942
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The ISPOR Good Practices for Quality Improvement of Cost-Effectiveness Research Task Force Report.
    McGhan WF; Al M; Doshi JA; Kamae I; Marx SE; Rindress D
    Value Health; 2009; 12(8):1086-99. PubMed ID: 19744291
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Azacitidine for Treating Acute Myeloid Leukaemia with More Than 30 % Bone Marrow Blasts: An Evidence Review Group Perspective of a National Institute for Health and Care Excellence Single Technology Appraisal.
    Tikhonova IA; Hoyle MW; Snowsill TM; Cooper C; Varley-Campbell JL; Rudin CE; Mujica Mota RE
    Pharmacoeconomics; 2017 Mar; 35(3):363-373. PubMed ID: 27752999
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Technology assessment in the German context.
    Drummond M
    Eur J Health Econ; 2007 Sep; 8 Suppl 1():S3. PubMed ID: 17619919
    [No Abstract]   [Full Text] [Related]  

  • 25. Clinical Outcomes of Geriatric Care in Cipto Mangunkusumo Hospital, Before and After the Implementation of National Health Insurance Program.
    Soejono CH; Padmawati RS; Utarini A
    Acta Med Indones; 2017 Oct; 49(4):336-342. PubMed ID: 29348384
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of orlistat in the management of obesity.
    O'Meara S; Riemsma R; Shirran L; Mather L; ter Riet G
    Health Technol Assess; 2001; 5(18):1-81. PubMed ID: 11399238
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Multicriteria decision analysis (MCDA) for health technology assessment: the Queensland Health experience.
    Howard S; Scott IA; Ju H; McQueen L; Scuffham PA
    Aust Health Rev; 2019 Oct; 43(5):591-599. PubMed ID: 30205873
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparing the ICERs in Medicine Reimbursement Submissions to NICE and PBAC-Does the Presence of an Explicit Threshold Affect the ICER Proposed?
    Wang S; Gum D; Merlin T
    Value Health; 2018 Aug; 21(8):938-943. PubMed ID: 30098671
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Strengthening cost-effectiveness analysis in Thailand through the establishment of the health intervention and technology assessment program.
    Tantivess S; Teerawattananon Y; Mills A
    Pharmacoeconomics; 2009; 27(11):931-45. PubMed ID: 19888793
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Quality-adjusted life-years lack quality in pediatric care: a critical review of published cost-utility studies in child health.
    Griebsch I; Coast J; Brown J
    Pediatrics; 2005 May; 115(5):e600-14. PubMed ID: 15867026
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Review of the Methods Used to Generate Utility Values in NICE Technology Assessments for Children and Adolescents.
    Hill H; Rowen D; Pennington B; Wong R; Wailoo A
    Value Health; 2020 Jul; 23(7):907-917. PubMed ID: 32762993
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The South African Guidelines for Pharmacoeconomic Submissions' Evidence Requirements Compared with Other African Countries and The National Institute for Health and Care Excellence in England.
    Marsh SE; Truter I
    Expert Rev Pharmacoecon Outcomes Res; 2020 Apr; 20(2):155-168. PubMed ID: 31056961
    [No Abstract]   [Full Text] [Related]  

  • 33. Review of guidelines for good practice in decision-analytic modelling in health technology assessment.
    Philips Z; Ginnelly L; Sculpher M; Claxton K; Golder S; Riemsma R; Woolacoot N; Glanville J
    Health Technol Assess; 2004 Sep; 8(36):iii-iv, ix-xi, 1-158. PubMed ID: 15361314
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Systematic searching and selection of health state utility values from the literature.
    Papaioannou D; Brazier J; Paisley S
    Value Health; 2013 Jun; 16(4):686-95. PubMed ID: 23796303
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.
    Forbes C; Shirran L; Bagnall AM; Duffy S; ter Riet G
    Health Technol Assess; 2001; 5(28):1-110. PubMed ID: 11701100
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cannabidiol for Adjuvant Treatment of Seizures Associated with Lennox-Gastaut Syndrome and Dravet Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Wijnen B; Armstrong N; Ramaekers B; Witlox W; Westwood M; Fayter D; Ryder S; Buksnys T; Worthy G; Misso K; Grimm S; Kleijnen J; Joore M
    Pharmacoeconomics; 2020 Oct; 38(10):1043-1053. PubMed ID: 32514751
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Technology assessment and cost-effectiveness analysis: misguided guidelines?
    Naylor CD; Williams JI; Basinski A; Goel V
    CMAJ; 1993 Mar; 148(6):921-4. PubMed ID: 8448706
    [No Abstract]   [Full Text] [Related]  

  • 38. Utility values in health technology assessments: a statistician's perspective.
    Whately-Smith C; Watkins C; Mann H; Fletcher C; Ducournau P
    Pharm Stat; 2014; 13(3):184-95. PubMed ID: 24692364
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Towards Actualizing the Value Potential of Korea Health Insurance Review and Assessment (HIRA) Data as a Resource for Health Research: Strengths, Limitations, Applications, and Strategies for Optimal Use of HIRA Data.
    Kim JA; Yoon S; Kim LY; Kim DS
    J Korean Med Sci; 2017 May; 32(5):718-728. PubMed ID: 28378543
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-utility analysis of the National Health Screening Program for chronic kidney disease in Korea.
    Go DS; Kim SH; Park J; Ryu DR; Lee HJ; Jo MW
    Nephrology (Carlton); 2019 Jan; 24(1):56-64. PubMed ID: 29206319
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.